Outcomes of Treatment for HIV-Infected Lymphoma Patients: A National Cancer Database (NCDB) Analysis

Publication date: Available online 13 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Yazan Samhouri, Rodney E. Wegner, Santhosh Sadashiv
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in the bone marrow, accounting for 1% of all cancers and ∼10% of all hematological malignancies.1 MM diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more MM defining events: CRAB features related to the plasma cell disorder (i.e., hypercalcemia [C], renal failure [R], anemia [A], or lytic bone lesions [B]), bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or>1 focal lesion on magnetic res...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
In this study, we applied this novel measure to examine trends in premature mortality caused by hematological cancers in Canada from 1980 to 2015. Mortality data for Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and leukemia were obtained from the World Health Organization mortality database. Years of life lost was calculated according to Canadian life tables. ALSS was defined as the ratio between years of life lost and expected lifespan. Over the study period, age standardized rates of mortality decreased for all types of hematological cancers. Our new ALSS measure showed favorable trends in premature mort...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
We queried the National Cancer Database for stage I-II Hodgkin lymphoma patients and analyzed radiation dose in patients receiving combined modality therapy (CMT). We show higher use of 20Gy as a component of CMT after 2010, the year of HD10 publication.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We describe current and future therapeutic application of CRISPR/Cas9 technology with the focus on the production and applications of engineered hematopoietic and immune cells against lymphoid malignancies. Furthermore, we provide an overview of the possible challenges and optimization of CRISPR/Cas9 system for ex- and in vivo applications within recent years. PMID: 32687855 [PubMed - as supplied by publisher]
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Publication date: Available online 14 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jin Zhao, Liping Su, Jinghua Zhong
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We hypothesized that higher Charlson comorbidity index(CCI) predicts worse one-month mortality and overall survival(OS) in patients ≥60 years with acute myeloid leukemia(AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplant. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared to CCI 0.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 14 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jin Zhao, Liping Su, Jinghua Zhong
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Yazan Samhouri, Rodney E. Wegner, Santhosh Sadashiv
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We assessed the risk factors for cancer-specific mortality and cardiovascular mortality in 62,950 patients with diffuse large B-cell lymphoma. Our results showed that age at diagnosis, married status, black race, and higher tumor stage were associated with an increased risk of cancer-specific mortality in patients with diffuse large B-cell lymphoma, whereas age at diagnosis and black race were associated with a higher risk of cardiovascular mortality.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Leukemia | Lymphoma | Myeloma